The following list of abstracts represent a small portion of our involvement in virology and oncology research. For any requests before 2010, please contact us.

2011

Dua R, Zhang J, Parry G, Penuel E. Detection of Hepatocyte Growth Factor (HGF) Ligand-c-MET Receptor Activation in Formalin-Fixed Paraffin Embedded Specimens by a Novel Proximity Assay. PLoS One. 2011 Jan 21;6(1):e15932.
(PDF)

2010

Nancy A. Hessol, Laura A. Napolitano, Dawn Smith, Yolanda Lie, Alexandra Levine, Mary Young, Mardge Cohen, Howard Minkoff, Kathryn Anastos, Gypsyamber D’Souza, Ruth M. Greenblatt, James J. Goedert. HIV TROPISM AND DECREASED RISK OF BREAST CANCER. PLoS One. 2010 Dec 16;5(12):e14349.
(PDF)

Smith DH, Winters-Digiacinto P, Mitiku M, O'Rourke S, Sinangil F, Wrin T, Montefiori DC, Berman PW. Comparative Immunogenicity of HIV-1 Clade C Envelope Proteins for Prime/Boost Studies. PLoS One. 2010 Aug 11;5(8). pii: e12076.
(PDF)

Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, Decamp A, Giganti M, Berman PW, Self SG, Montefiori DC. Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV-1 gp120 Vaccine. J Infect Dis. 2010 Aug 15;202(4):595-605.
(PDF)

Larson JS, Goodman LJ, Tan Y, Defazio-Eli L, Paquet AC, Cook JW, Rivera A, Frankson K, Bose J, Chen L, Cheung J, Shi Y, Irwin S, Kiss LD, Huang W, Utter S, Sherwood T, Bates M, Weidler J, Parry G, Winslow J, Petropoulos CJ, Whitcomb JM. Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens. Patholog Res Int. 2010 Jun 28;2010:814176.
(PDF)

Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob Agents Chemother. 2010 May;54(5):1973-80.
(PDF)

Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C, Gorny MK, Zolla-Pazner S. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One. 2010 Apr 21;5(4):e10254.
(PDF)

Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis. 2010 Apr 1;201(7):1045-53.
(PDF)

van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, Schuitemaker H. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J Virol. 2010 Apr;84(7):3576-85.
(PDF)

Toi M, Sperinde J, Huang W, Saji S, Winslow J, Jin X, Tan Y, Ohno S, Nakamura S, Iwata H, Masuda N, Aogi K, Morita S, Petropoulos C, Bates M. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. BMC Cancer. 2010 Feb 23;10:56.
(PDF)

Schweighardt B, Wrin T, Meiklejohn DA, Spotts G, Petropoulos CJ, Nixon DF, Hecht FM. Immune Escape Mutations Detected Within HIV-1 Epitopes Associated With Viral Control During Treatment Interruption. J Acquir Immune Defic Syndr. 2010 Jan 1;53(1):36-46.
(PDF)

van Gils MJ, Edo-Matas D, Schweighardt B, Wrin T, Schuitemaker H. High Prevalence of Neutralizing Activity against Multiple Unrelated HIV-1 Subtype B Variants in Sera from HIV-1 Subtype B Infected Individuals: Evidence for Subtype Specific Rather than Strain Specific Neutralizing Activity. J Gen Virol. 2010 January; 91(Pt 1): 250-258.
(PDF)